Premium
Human medulloblastomas lack point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene
Author(s) -
Kraus J. A.,
Oster C.,
Sörensen N.,
Berthold F.,
Schlegel U.,
Tonn J. C.,
Wiestler O. D.,
Pietsch T.
Publication year - 2002
Publication title -
neuropathology and applied neurobiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.538
H-Index - 95
eISSN - 1365-2990
pISSN - 0305-1846
DOI - 10.1046/j.1365-2990.2002.00388.x
Subject(s) - medulloblastoma , tumor suppressor gene , suppressor , point mutation , gene , smarcb1 , monosomy , biology , mutation , cancer research , chromosome 22 , chromosome , genetics , carcinogenesis , gene expression , karyotype , chromatin remodeling
Medulloblastomas (MBs) are malignant primitive neuroectodermal tumours (PNETs) of the cerebellum occurring predominantly in childhood. The association of monosomy of chromosome 22 with MB is controversial. Atypical teratoid/rhabdoid tumours (AT/RTs) of the brain share clinical and histological features with MBs and supratentorial PNETs (sPNETs). In particular, AT/RTs can be misdiagnosed as MBs and sPNETs because AT/RTs frequently contain areas of primitive neuroepithelial cells similar to PNETs. Recently, mutations of the tumour suppressor gene hSNF5/INI1 , located on 22q11.23, have been described in AT/RTs, MBs and sPNETs, with conflicting data on the prevalence of hSNF5/INI1 mutations in the latter entities. Therefore, we screened MBs for point mutations and homozygous deletions of the hSNF5/INI1 tumour suppressor gene. In 90 MBs, no mutations of the hSNF5/INI1 gene were identified. Thus, our study virtually rules out hSNF5/INI1 as a tumour suppressor gene involved in the pathogenesis of medulloblastoma.